Bright Minds Biosciences Statistics
Total Valuation
DRUG has a market cap or net worth of $4.71 million. The enterprise value is -$228,844.
Market Cap | 4.71M |
Enterprise Value | -228,844 |
Important Dates
The next estimated earnings date is Tuesday, May 14, 2024, before market open.
Earnings Date | May 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
DRUG has 4.32 million shares outstanding. The number of shares has increased by 7.13% in one year.
Shares Outstanding | 4.32M |
Shares Change (YoY) | +7.13% |
Shares Change (QoQ) | +1.86% |
Owned by Insiders (%) | 35.72% |
Owned by Institutions (%) | 5.15% |
Float | 3.18M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.07 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.01, with zero debt.
Current Ratio | 8.01 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -91.70% and return on invested capital (ROIC) is -112.50%.
Return on Equity (ROE) | -91.70% |
Return on Assets (ROA) | -83.50% |
Return on Capital (ROIC) | -112.50% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.50% in the last 52 weeks. The beta is 1.53, so DRUG's price volatility has been higher than the market average.
Beta (1Y) | 1.53 |
52-Week Price Change | -61.50% |
50-Day Moving Average | 1.45 |
200-Day Moving Average | 1.86 |
Relative Strength Index (RSI) | 35.53 |
Average Volume (30 Days) | 24,950 |
Short Selling Information
The latest short interest is 70,630, so 1.64% of the outstanding shares have been sold short.
Short Interest | 70,630 |
Short Previous Month | 73,200 |
Short % of Shares Out | 1.64% |
Short % of Float | 2.22% |
Short Ratio (days to cover) | 3.12 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -4.96M |
Pretax Income | -4.91M |
Net Income | -5.05M |
EBITDA | -4.85M |
EBIT | -4.91M |
Earnings Per Share (EPS) | -$1.30 |
Balance Sheet
The company has $4.94 million in cash and no debt, giving a net cash position of $4.94 million or $1.14 per share.
Cash & Cash Equivalents | 4.94M |
Total Debt | n/a |
Net Cash | 4.94M |
Net Cash Per Share | $1.14 |
Equity / Book Value | 4.41M |
Book Value Per Share | 1.02 |
Working Capital | 4.37M |
Cash Flow
Operating Cash Flow | -3.78M |
Capital Expenditures | n/a |
Free Cash Flow | -3.78M |
FCF Per Share | -$0.99 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.13% |
Shareholder Yield | -7.13% |
Earnings Yield | -107.32% |
FCF Yield | -80.37% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.
Last Split Date | Jul 14, 2023 |
Split Type | Reverse |
Split Ratio | 1:5 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |